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Identity 
HGNC (Hugo) 
BAP1 
Location 
3p21.1 
Other names 
DKFZp686N04275, FLJ35406, FLJ37180, HUCEP-
13, KIAA0272, UCHL2, hucep-6 
DNA/RNA 
Description 
The gene spans 9.0 kb and is composed of 17 exons. 
Transcription 
Transcription start is 115 bp upstream of first ATG 
of the BAP1 ORF. 
Pseudogene 
No pseudogene reported. 
Protein 
Structure of BAP1. BAP1 is a 729 aa protein. UCH, Ubiquitin C-terminal hydrolase; HBM, HCF-binding motif 
(NHNY sequence); NLS, Nuclear localization signal. 
Description 
Human BAP1 is 729 amino acids with a molecular 
weight of 90 kDa. The amino-terminal 240 amino 
acids show homology to ubiquitin C-terminal 
hydrolases (UCH). 
BAP1 also contains a region of extreme acidity 
(amino acids 396 to 408), multiple potential 
phosphorylation sites and N-linked glycosylation 
sites. The C-terminal region contains two putative 
nuclear localization signals. 
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BAP1 binds to the RING finger domain of BRCA1 
through its carboxyl-terminal region (594-657 amino 
acids). Domain comprised by residues 182-365 of 
BAP1 interacts with the RING finger domain of 
BARD1. Interaction of BAP1 with HCF-1 (host cell 
factor 1; HCFC1) is dependent on the NHNY 
sequence resembling the HCF-binding motif 
(HBM). 
Expression 
BAP1 is expressed in a variety of human adult 
tissues. High expression was detected in testis, 
placenta and ovary, with varying levels detected in 
other tissues. Expression of BAP1 in normal human 
breast tissue was also detected. 
Analysis conducted in mice revealed that Bap1 
expression is up-regulated in the breast during 
puberty, pregnancy and as a result of parity. 
BAP1 mRNA level is significantly increased in 
MCF10a cell line following genistein treatment, an 
isoflavone found in soya and proposed to prevent 
breast cancer. 
Localisation 
BAP1 is a nuclear-localized ubiquitin carboxy-
terminal hydrolase. 
Function 
BAP1 enhances BRCA1-mediated inhibition of 
breast cancer cell growth and may serve as a 
regulator/effector of BRCA1 growth 
control/differentiation pathways. BAP1 interacts 
with HCF-1, a transcriptional cofactor found in a 
number of important regulatory complexes. Bap1 
may help to control cell proliferation by regulating 
HCF-1 protein levels and by associating with genes 
involved in the G1-S transition. 
The BRCA1/BARD1 complex possess a dual E3 
ubiquitin ligase activity, promotes its own 
ubiquitination and targets other proteins. Although 
BAP1 associates with BRCA1, it does not appear to 
function in the deubiquitylation of the 
BRCA1/BARD1 complex. BAP1 inhibits the E3 
ligase activity of BRCA1/BARD1 by binding the 
RING finger domain of BARD1 and possesses 
deubiquitination activity toward ubiquitin chains 
catalyzed by BRCA1/BARD1. 
BAP1 and BRCA1/BARD1 may coordinately 
regulate ubiquitination during the DNA damage 
response and the cell cycle, BAP1 being 
phosphorylated by ATM and ATR in response to 
DNA damage and BAP1 inhibition causing S-phase 
retardation. 
It was also proposed that specific regions and UCH 
activity of BAP1 play an essential role in TCR. 
In the cytoplasm, BAP1 has recently been shown to 
localize at the endoplasmic reticulum, where it 
binds, deubiquitylates, and stabilizes type 3 inositol-
1,4,5-trisphosphate receptor (IP3R3). This binding 
modulates calcium (Ca2+) release from the 
endoplasmic reticulum into the cytosol and 
mitochondria, promoting apoptosis. 
Homology 
The amino-terminal 240 amino acids show 
significant homology to a class of thiol proteases, 
designated UCH, which are implicated in the 
proteolytic processing of ubiquitin. 
Mutations 
Note 
The mutation of a residue predicted to disrupt the 
helical nature of the extreme C-terminal region of 
BAP1 abolishes the BAP1/BRCA1 interaction. 
BAP1 can suppress tumorigenicity of lung cancer 
cells in athymic nude mice. 
Deubiquitinating activity and nuclear localization 
are both required for BAP1-mediated tumor 
suppression. Moreover, BAP1-mediated growth 
suppression is independent of wild-type BRCA1. 
 
Squamous-cell carcinomas and large-cell 
undifferentiated carcinomas showed LOH for a 
3p21-22 locus. 
Large rearrangements, deletions, and missense 
mutations of the BAP1 locus have been found in lung 
and sporadic breast tumors and in lung cancer cell 
lines.  
Heterozygous germline mutations of Bap1 in mice 
predispose to tumor formation, providing in vivo 
evidence that Bap1 Is a bona fide tumor suppressor.  
Bap1+/- mice followed for up to 20 months of age 
demonstrated that haploinsufficient mutant mice 
exhibited a markedly higher incidence and 
accelerated onset of asbestos-induced malignant 
mesothelioma when compared with similarly-
exposed wild-type littermates. 
Implicated in 
Breast cancer 
A study conducted on high-risk breast cancer 
families from the French population revealed that the 
BAP1 gene does not appear to be commonly 
involved in high-risk breast cancer predisposition. 
These results were thereafter confirmed in a larger 
study conducted on families with high risk of breast 
cancer from the French Canadian population. These 
studies do not rule out the possibility that BAP1 
alleles might be associated with moderate or low 
breast cancer risk. 
 
Selected variations of the BAP1 gene were also 
excluded as low penetrance risk alleles in sporadic 
breast cancer carried from the Spanish population. 
Medulloblastoma 
Medulloblastoma is a highly malignant tumor of the 
cerebellum. This disease with poor prognosis occurs 
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mostly in children. A screen of cDNA libraries with 
autologous sera to identify antigen-specific immune 
responses associated with this agressive tumor type 
pointed to the BAP1 gene as a possible target of 
immune response. 
Malignant Pleural Mesothelioma 
(MPM) 
MPM is a lethal disease resistant to most current 
therapies.  In 2011, two independent investigations 
identified somatic BAP1 mutations in sporadic 
MPMs, and one report also identified families with 
MPMs resulting from germline mutations of BAP1.  
To date, BAP1 mutations have been found in 47-
67% of sporadic MPM tumors, with 20-25% 
involving truncating point mutations and the 
remainder involving exonic deletions.  The 
mutations occur mostly in epithelioid MPM (and 
many peritoneal mesotheliomas) and no significant 
correlation has been found between somatic 
mutation in BAP1 and gender, exposure to asbestos, 
or survival. 
Abnormal protein 
Identified in pleural malignant mesothelioma 
specimens by RNA-seq data analysis:  
BAP1 (3p21.1) / CCDC66 (3p14.3) (validated by 
Sanger sequencing)  
BAP1 (3p21.1) / WDR6 (3p21.31)  
BAP1 (3p21.1) / ALDH3B1 (11q13.2)  
BAP1 (3p21.1) / TNNC1 (3p21.1)  
BAP1 (3p21.1) / PBRM1 3p21.1 (validated by 
Sanger sequencing) 
Familial Mesothelioma 
Metastatic Uveal Melanoma 
Inactivating somatic mutations of BAP1 have been 
reported in nearly 85% of metastasizing uveal 
melanomas, the most common primary cancer of the 
eye and a tumor type with a strong propensity for 
fatal metastasis.  More than one half of the mutations 
were predicted to cause premature protein 
termination, and about 20% affected BAP1's 
ubiquitin carboxyl-terminal hydrolase domain. 
Cutaneous Melanoma 
Somatic mutations have been observed in about 5% 
of spontaneous cutaneous melanomas and 10% of 
atypical Spitz tumors. 
Clear Cell Renal Cell Carcinoma 
BAP1 is inactivated in about 15% of clear cell renal 
cell carcinomas (ccRCCs).  Notably, BAP1 loss is a 
poor prognostic indicator in ccRCC, being 
associated with high tumor grade. 
Intrahepatic Cholangiocarcinoma 
Somatic BAP1 mutations were reported in 8 of 32 
(25%) intrahepatic cholangiocarcinomas in a 
discovery screen and in 5 of 32 (16%) independent 
intrahepatic cholangiocarcinomas in a subsequent 
prevalence screen. 
Schizophrenia 
The BAP1 gene was excluded as a promizing 
candidate gene for schizophrenia in a fine mapping 
association study carried out on chromosome 3p, one 
of the regions showing strong evidence of linkage 
with schizophrenia. 
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